These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 31306750)

  • 21. Physiologically based pharmacokinetic combined BTK occupancy modeling for optimal dosing regimen prediction of acalabrutinib in patients alone, with different CYP3A4 variants, co-administered with CYP3A4 modulators and with hepatic impairment.
    Xu L; Yu S; Liu H; Yi B; Wang G; Liu Y
    Eur J Clin Pharmacol; 2022 Sep; 78(9):1435-1446. PubMed ID: 35680661
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In silico modeling for the nonlinear absorption kinetics of UK-343,664: a P-gp and CYP3A4 substrate.
    Abuasal BS; Bolger MB; Walker DK; Kaddoumi A
    Mol Pharm; 2012 Mar; 9(3):492-504. PubMed ID: 22264132
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An in vitro-in vivo correlation study for nifedipine immediate release capsules administered with water, alcoholic and non-alcoholic beverages: Impact of in vitro dissolution media and hydrodynamics.
    Mercuri A; Fares R; Bresciani M; Fotaki N
    Int J Pharm; 2016 Feb; 499(1-2):330-342. PubMed ID: 26721731
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of the drug-drug interactions potential of ibrutinib and acalabrutinib via inhibition of UDP-glucuronosyltransferase.
    Wang X; Wang Z; Fan X; Yan M; Jiang L; Xia Y; Cao J; Liu Y
    Toxicol Appl Pharmacol; 2021 Aug; 424():115595. PubMed ID: 34038714
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim.
    Sjögren E; Westergren J; Grant I; Hanisch G; Lindfors L; Lennernäs H; Abrahamsson B; Tannergren C
    Eur J Pharm Sci; 2013 Jul; 49(4):679-98. PubMed ID: 23727464
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Physiologically Based Absorption Modelling to Explore the Impact of Food and Gastric pH Changes on the Pharmacokinetics of Entrectinib.
    Parrott N; Stillhart C; Lindenberg M; Wagner B; Kowalski K; Guerini E; Djebli N; Meneses-Lorente G
    AAPS J; 2020 May; 22(4):78. PubMed ID: 32458089
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Establishing Virtual Bioequivalence and Clinically Relevant Specifications for Omeprazole Enteric-Coated Capsules by Incorporating Dissolution Data in PBPK Modeling.
    Yang R; Lin Y; Chen K; Huang J; Yang S; Yao A; Yang X; Lei D; Xiao J; Yang G; Pei Q
    AAPS J; 2024 Jul; 26(4):82. PubMed ID: 38997548
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro dissolution of proton-pump inhibitor products intended for paediatric and geriatric use in physiological bicarbonate buffer.
    Liu F; Shokrollahi H
    Int J Pharm; 2015 May; 485(1-2):152-9. PubMed ID: 25746736
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mechanistic understanding of the effect of PPIs and acidic carbonated beverages on the oral absorption of itraconazole based on absorption modeling with appropriate in vitro data.
    Fotaki N; Klein S
    Mol Pharm; 2013 Nov; 10(11):4016-23. PubMed ID: 23947755
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Amorphous Solid Dispersion Tablets Overcome Acalabrutinib pH Effect in Dogs.
    Mudie DM; Stewart AM; Rosales JA; Biswas N; Adam MS; Smith A; Craig CD; Morgen MM; Vodak DT
    Pharmaceutics; 2021 Apr; 13(4):. PubMed ID: 33921109
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Integration of dissolution into physiologically-based pharmacokinetic models III: PK-Sim®.
    Willmann S; Thelen K; Lippert J
    J Pharm Pharmacol; 2012 Jul; 64(7):997-1007. PubMed ID: 22686345
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Negative Food Effect of Danirixin: Use of PBPK Modelling to Explore the Effect of Formulation and Meal Type on Clinical PK.
    Lloyd RS; Hingle MI; Bloomer JC; Charles SJ; Butler JM; Paul A; Zhu X; Miller B; D'Amico D; Donald A; Tal-Singer R; Ambery C
    Pharm Res; 2020 Oct; 37(12):233. PubMed ID: 33123802
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prediction of plasma profiles of a weakly basic drug after administration of omeprazole using PBPK modeling.
    Segregur D; Mann J; Moir A; Karlsson EM; Dressman J
    Eur J Pharm Sci; 2021 Mar; 158():105656. PubMed ID: 33253885
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mechanistic Assessment of the Effect of Omeprazole on the In Vivo Pharmacokinetics of Itraconazole in Healthy Volunteers.
    Abuhelwa AY; Mudge S; Upton RN; Foster DJR
    Eur J Drug Metab Pharmacokinet; 2019 Apr; 44(2):201-215. PubMed ID: 30328059
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Phase 1 Pharmacokinetic Study of Cysteamine Bitartrate Delayed-Release Capsules Following Oral Administration with Orange Juice, Water, or Omeprazole in Cystinosis.
    Armas D; Holt RJ; Confer NF; Checani GC; Obaidi M; Xie Y; Brannagan M
    Adv Ther; 2018 Feb; 35(2):199-209. PubMed ID: 29411268
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Justification of Biowaiver and Dissolution Rate Specifications for Piroxicam Immediate Release Products Based on Physiologically Based Pharmacokinetic Modeling: An In-Depth Analysis.
    Li X; Yang Y; Zhang Y; Wu C; Jiang Q; Wang W; Li H; Li J; Luo C; Wu W; Wang Y; Zhang T
    Mol Pharm; 2019 Sep; 16(9):3780-3790. PubMed ID: 31398041
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Application of Physiologically Based Pharmacokinetic Modeling in Understanding Bosutinib Drug-Drug Interactions: Importance of Intestinal P-Glycoprotein.
    Yamazaki S; Loi CM; Kimoto E; Costales C; Varma MV
    Drug Metab Dispos; 2018 Aug; 46(8):1200-1211. PubMed ID: 29739809
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mechanistic Physiologically Based Pharmacokinetic Modeling of the Dissolution and Food Effect of a Biopharmaceutics Classification System IV Compound-The Venetoclax Story.
    Emami Riedmaier A; Lindley DJ; Hall JA; Castleberry S; Slade RT; Stuart P; Carr RA; Borchardt TB; Bow DAJ; Nijsen M
    J Pharm Sci; 2018 Jan; 107(1):495-502. PubMed ID: 28993217
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Physiologically based predictions of the impact of inhibition of intestinal and hepatic metabolism on human pharmacokinetics of CYP3A substrates.
    Fenneteau F; Poulin P; Nekka F
    J Pharm Sci; 2010 Jan; 99(1):486-514. PubMed ID: 19479982
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Performance Evaluation of Montelukast Pediatric Formulations: Part II - a PBPK Modelling Approach.
    Guimarães M; Vertzoni M; Fotaki N
    AAPS J; 2022 Jan; 24(1):27. PubMed ID: 35013803
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.